EUVIMEDEUVIMED entdecken
Crossref

Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids

Kevin E. Noonan, Andrew W. Torrance

SMU Science and Technology Law Review · 10.04.2026 · 28 (2) · 579

DOI: 10.25172/smustlr.28.2.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SMU Science and Technology Law Review, online erschienen am 10.04.2026. Verfasst von Kevin E. Noonan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A pivotal year for biotechnology patent law, 2024 was marked by consequential court rulings and evolving legal frameworks. This article surveys the ten most significant judicial decisions impacting biotech patents, highlighting major themes and trends in policy, litigation, and regulation. Courts at all levels grappled with core patentability requirements in the life sciences, from the Supreme Court’s continued laissez-faire stance on subject-matter eligibility to the Federal Circuit’s stringent enforcement of disclosure sufficiency rules. Notably, the year’s decisions reinforced a high bar for patent enablement and written description in biotech inventions in the wake of Amgen v. Sanofi, while attempting (not always consistently) to clarify doctrines such as obviousness-type double patenting in the context of patent term adjustments. At the same time, judicial opinions refined the balance between innovation incentives and market competition: in the pharmaceutical arena, courts addressed the limits of generic drug competition and “skinny labels” for off-patent uses, as well as the enforceability of post-expiration royalty agreements in biotech licenses. Another key trend was the heightened scrutiny of collaborative research arrangements—illustrated by a ruling extending government license rights under the Bayh-Dole Act to inventions conceived prior to federal funding—underscoring the need for clear contracting in research and development. Finally, the backdrop of administrative law shifts (such as the end of Chevron deference) and the advent of Europe’s Unified Patent Court provided a broader context in which these decisions unfolded. Together, the top ten decisions of 2024 reveal a patent law landscape in refinement, with courts actively calibrating legal doctrines to foster clarity and stability for the biotechnology sector.

Zitieren

APA

Noonan, K. E., & Torrance, A. W. (2026). Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids. SMU Science and Technology Law Review, 28(2), 579. https://doi.org/10.25172/smustlr.28.2.5

Vancouver

Noonan KE, Torrance AW. Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids. SMU Science and Technology Law Review. 2026;28(2):579. doi:10.25172/smustlr.28.2.5

BibTeX
@article{Noonan2026,
  author = {Noonan, Kevin E. and Torrance, Andrew W.},
  title = {Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids},
  journal = {SMU Science and Technology Law Review},
  year = {2026},
  volume = {28},
  number = {2},
  pages = {579},
  doi = {10.25172/smustlr.28.2.5}
}
Kostenlos starten →